Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
04/09/2026 20:44
BRIEF-US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation Sept 4 (Reuters) - FDA:
US FDA - GRANTS ACCELERATED APPROVAL TO ETCAMAH FOR ADVANCED BREAST CANCER WITH ESR1 MUTATION
US FDA - AUTHORIZES GUARDANT360 CDX ASSAY AS COMPANION DIAGNOSTIC FOR BREAST CANCER
Further company coverage: AZN.L
Recent news on Guardant Health
See all newsBrief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment